% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

hokiestock 2 posts  |  Last Activity: Jan 30, 2016 10:06 PM Member since: Jul 10, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • hokiestock hokiestock Jan 30, 2016 10:06 PM Flag

    “In 2016, I hope that there will be significant progress in the treatment of brain tumors with hopefully positive trials of the EGFRvIII vaccine rindopepimut for newly diagnosed glioblastomas and checkpoint inhibitors for recurrent glioblastomas. 2016 will hopefully also see the launch of major Bayesian biomarker-driven adaptive design trials such as INSIGHT and GBM AGILE that will hopefully accelerate the development of new therapies for our patients.” – Dr. Patrick Wen, Dana-Farber Cancer Institute

  • Aduro and Celldex have almost identical charts over the last month. Seems to be a common theme driving down stocks with antibody and vaccine platforms. Sorrento is in same boat.
    23 trials now registered in EGFV111 for companies. Duke is doing Car-T EGFVv111 for glioblastoma. Seems Celldex started that trend. There appears to be too much literature any more around these mechanism of action around glio. Many of the other companies are trying to combine dual mechanism of action along with their EGFRV111. What appears to be the case is the market needs EGFRv111 mechanism of action and it will take years to find the right combo but anything is more than evident that Rindo needs to be approved to further development around glio and give confidence to others following steps. Rindo approval will only be the first step in cancer combination therapy for glioblastoma..

1.590.00(0.00%)Jul 25 4:00 PMEDT